Cost Consequence Analysis
Reviewed byRemya Krishnan
Definition
Cost consequence analysis (CCA) is a form of economic evaluation that presents the costs and multiple outcomes of two or more alternatives in a disaggregated format, listing each cost and consequence separately without combining them into a single summary ratio.[2][3] Unlike cost effectiveness or cost utility analysis, which produce incremental ratios, CCA displays all the relevant inputs and outputs in a tabular format, allowing decision makers to weigh the components according to their own values and priorities.[3] CCA is sometimes described as the most transparent form of economic evaluation because it makes all trade offs visible.
Explore the concept
Every row on the table
Read a pharmacy medication review's costs and outcomes row by row through three readers' eyes, then squash the table into one ratio and see what drops out.
Six months, per patient
Extra direct cost per patient
+120 USDAdverse drug events per 10 patients
FewerEmergency department visits per patient
FewerMedication adherence
Modestly higherPatient satisfaction, 0 to 10
SimilarCosts and consequences, side by side
The big idea: A cost consequence analysis lists each alternative's costs and outcomes side by side without combining them into one ratio, so each decision maker can weigh the rows by their own priorities. That transparency comes with a cost: readers can reach different conclusions, so the table should be clear, focused on the outcomes that matter and report uncertainty.
Figures follow the article's community pharmacy medication review example over six months: the review costs 120 USD more per patient; adverse drug events 2.1 vs 4.8 per 10 patients, emergency department visits 0.3 vs 0.7 per patient, adherence 85% vs 78%, satisfaction 8.2 vs 8.0 on a 10 point scale. The ratios are computed here only to show the effect of choosing a denominator: 120 / 0.4 = 300 USD per visit avoided, 120 / 0.27 = about 444 USD per adverse event avoided, 120 / 7 = about 17 USD per adherence point; they use the 120 USD direct cost difference without any downstream savings. No uncertainty ranges are given for the example, so none are drawn. The readers and the rows they weigh first follow the example.
Why it matters
CCA is particularly useful when an intervention produces multiple outcomes that cannot easily be reduced to a single metric. A complex public health intervention might simultaneously reduce hospitalizations, improve quality of life, decrease caregiver burden, and increase patient satisfaction. Combining all of these into a single cost per QALY ratio may obscure important differences that matter to different stakeholders. CCA presents the full picture, empowering decision makers, whether they are clinicians, policymakers, patients, or funders, to assign their own weights to different outcomes. It is also valuable as a precursor to more formal economic evaluations, providing the data needed to construct cost effectiveness or cost utility ratios later.[3]
How it works
Researchers measure the costs of each alternative, broken down into relevant categories (direct medical costs, direct nonmedical costs, indirect costs, and out of pocket costs). They then measure all important outcomes, which may span clinical endpoints, patient reported outcomes, process measures, and resource utilization. The results are presented in a summary table that lists each cost category and each outcome measure for each alternative side by side.[3] No single summary statistic is calculated. Decision makers examine the table and draw their own conclusions about which alternative represents the best value, given their particular priorities and context. Some researchers supplement the table with narrative interpretation, but the defining feature of CCA is that the components remain separate.
When to use it
CCA is appropriate when an intervention affects multiple outcomes that different stakeholders value differently. It is commonly used in evaluations of public health programs, integrated care models, and complex interventions where reducing outcomes to a single ratio would lose important information. CCA is also useful when there is no consensus on which outcome should serve as the denominator of a cost effectiveness ratio. Some health technology assessment agencies accept CCA alongside standard economic evaluations: the economic evaluation guidelines of Canada's Drug Agency (formerly CADTH), for example, treat a CCA as a complement to, not a substitute for, a cost utility analysis.[2]
Key takeaways
- CCA is particularly useful when an intervention produces multiple outcomes that cannot easily be reduced to a single metric.
- They then measure all important outcomes, which may span clinical endpoints, patient reported outcomes, process measures, and resource utilization.
- CCA is appropriate when an intervention affects multiple outcomes that different stakeholders value differently.
- A frequent criticism is that CCA leaves too much interpretation to the reader, making it possible for different stakeholders to reach different conclusions from the same data.
Common mistakes
- A frequent criticism is that CCA leaves too much interpretation to the reader, making it possible for different stakeholders to reach different conclusions from the same data. This is by design, but researchers should present the data clearly enough that the trade offs are evident.
- Another mistake is omitting important cost categories or outcomes, which undermines the comprehensiveness that is CCA's main advantage.
- Researchers sometimes present so many outcomes that the table becomes overwhelming; focusing on outcomes identified as important by stakeholders improves usability.
- Finally, failing to report confidence intervals or uncertainty ranges around costs and outcomes leaves decision makers unable to judge the precision of the estimates.
Example
Researchers evaluate a community pharmacy medication review service for elderly patients with polypharmacy. The CCA table compares the intervention (pharmacist led review plus follow up) with usual care across six months. Direct costs: the intervention costs $120 more per patient. Outcomes: the intervention group has fewer adverse drug events (2.1 vs 4.8 per 10 patients), fewer emergency department visits (0.3 vs 0.7 per patient), modestly higher medication adherence (85% vs 78%), and similar patient satisfaction scores (8.2 vs 8.0 on a 10 point scale). The disaggregated presentation allows health system administrators focused on emergency department costs, clinicians focused on adverse events, and patients focused on adherence to each identify the dimensions most relevant to their decisions.
Test your understanding
5 questions that adapt as you go: answer two in a row correctly and they get harder.
Question 1 of 5
Scenario:
A complex public health program reduces hospitalizations, improves quality of life, decreases caregiver burden and increases patient satisfaction. Funders, clinicians and patient groups disagree about which outcome matters most.
Question:
Which form of economic evaluation fits best?
Hardness: Interpret
Sources
- [1]Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford University Press, 2015. ISBN 9780199665884
- [2]CADTH. Guidelines for the Economic Evaluation of Health Technologies: Canada. 4th ed. Ottawa: CADTH; 2017. https://www.cda-amc.ca/guidelines-economic-evaluation-health-technologies-canada-4th-edition
- [3]Mauskopf JA, Paul JE, Grant DM, Stergachis A. The role of cost-consequence analysis in healthcare decision-making. PharmacoEconomics. 1998;13(3):277-288. doi:10.2165/00019053-199813030-00002
Cite this term
Paperguide. (2026, October 14). Cost Consequence Analysis. In Paperguide Research Glossary. https://paperguide.ai/research-glossary/cost-consequence-analysis/(Paperguide, 2026)